Testing sorafenib for new type 1 diabetes
Treatments studied
Part of Hormones & metabolism, Immune system & allergy clinical trials.
This trial tests whether sorafenib, a medicine that blocks certain growth signals, can help preserve the body's own insulin production in people newly diagnosed with type 1 diabetes. It aims to slow the loss of insulin-making cells and improve blood sugar control.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be between 18 and 60 years old.
- You were diagnosed with type 1 diabetes within the last year.
- You have at least one diabetes-related antibody in your blood (GAD, IA-2, or ZnT8).
- Your body still produces some insulin (C-peptide level above 200 pmol/L).
- You cannot have serious heart, liver, kidney, or blood disorders, or active infections.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests new treatments to protect the heart and kidneys in people with long-standing type 1 diabetes. It aims to prevent or slow down complications like heart failure and kidney damage.
This study tests a new drug called SAB-142, which aims to stop the immune system from attacking insulin-making cells in type 1 diabetes. It may help preserve your body's ability to make insulin. The trial will check if the drug is safe and effective.
This Phase 2 study tests whether starting with cyclosporine and then giving low-dose IL-2 can better protect the body’s insulin-producing function after type 1 diabetes is diagnosed. It’s meant for people diagnosed very recently who have specific diabetes-related immune markers.
This study tests two different medications (Anti-Thymocyte Globulin and Adalimumab or Verapamil) to see if they can slow down the loss of insulin production in people with newly diagnosed type 1 diabetes. Participants will be randomly assigned to receive one of the treatments and will be followed for about a year to see how well their bodies still make insulin.
This trial tests a new way to give a medicine called anti-thymocyte globulin (ATG) with or without verapamil, a blood pressure drug. It aims to slow down the loss of insulin-making cells in people newly diagnosed with type 1 diabetes.
This trial tests a combination of treatments to lower the risk of heart disease and kidney problems in people with type 1 diabetes who already have some complications or higher risk. If you qualify, you will receive extra care aimed at preventing heart attacks, strokes, and kidney failure.
Hear when a new Type 1 diabetes trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.